Skye Bioscience, Inc. financial data

Symbol
SKYE on Nasdaq
Industry
Pharmaceutical Preparations
Location
11250 El Camino Real, Suite 100, San Diego, CA
State of incorporation
NV
Fiscal year end
December 31
Former names
Emerald Bioscience, Inc. (to 1/7/2021), Nemus Bioscience, Inc. (to 3/14/2019), LOAD GUARD LOGISTICS, INC. (to 10/30/2014), LOAD GUARD TRANSPORTATION, INC. (to 11/7/2012)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 550 % +710%
Debt-to-equity 22.3 %
Return On Equity -37.7 % -103%
Return On Assets -30.8 % +94.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30.3M shares +146%
Common Stock, Shares, Outstanding 30.3M shares +146%
Entity Public Float 20.4M USD +17.5%
Common Stock, Value, Issued 30.3K USD +146%
Weighted Average Number of Shares Outstanding, Basic 38.8M shares +393%
Weighted Average Number of Shares Outstanding, Diluted 38.8M shares +393%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.29M USD +52.2%
General and Administrative Expense 15.7M USD +127%
Operating Income (Loss) -23.6M USD +40.9%
Nonoperating Income (Expense) 2.38M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -21.2M USD +50.8%
Income Tax Expense (Benefit) 10.1K USD
Net Income (Loss) Attributable to Parent -21.2M USD +50.7%
Earnings Per Share, Basic -0.51 USD/shares +95.9%
Earnings Per Share, Diluted -0.51 USD/shares +95.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 67.4M USD +1215%
Cash, Cash Equivalents, and Short-term Investments 0 USD
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Other Assets, Current 2.65M USD +205%
Assets, Current 79.8M USD +422%
Property, Plant and Equipment, Net 1.52M USD +2644%
Operating Lease, Right-of-Use Asset 185K USD -27.5%
Other Assets, Noncurrent 26.3K USD +217%
Assets 81.5M USD +423%
Accounts Payable, Current 780K USD -52.2%
Employee-related Liabilities, Current 903K USD +39.9%
Liabilities, Current 5.62M USD -59%
Operating Lease, Liability, Noncurrent 108K USD -43.3%
Liabilities 5.73M USD -58.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -121M USD -21.2%
Stockholders' Equity Attributable to Parent 75.8M USD +4371%
Liabilities and Equity 81.5M USD +423%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.71M USD -15.9%
Net Cash Provided by (Used in) Financing Activities 85.7M USD
Net Cash Provided by (Used in) Investing Activities 1.14M USD -79.4%
Common Stock, Shares Authorized 100M shares +400%
Common Stock, Shares, Issued 30.3M shares +146%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 82.1M USD +5664%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 76.5M USD +438%
Interest Paid, Excluding Capitalized Interest, Operating Activities 126K USD +2848%
Deferred Tax Assets, Valuation Allowance 66.5M USD +51.2%
Deferred Tax Assets, Gross 66.5M USD +51.3%
Operating Lease, Liability 243K USD +209%
Depreciation 27.6K USD -16.9%
Payments to Acquire Property, Plant, and Equipment 3.18K USD +71%
Lessee, Operating Lease, Liability, to be Paid 300K USD +261%
Property, Plant and Equipment, Gross 1.62M USD
Operating Lease, Liability, Current 82.9K USD +20.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 106K USD +27.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 103K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure +25%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 57.1K USD +1199%
Lessee, Operating Lease, Liability, to be Paid, Year Three 90.8K USD
Deferred Tax Assets, Operating Loss Carryforwards 40.9M USD +33.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200K shares 0%
Unrecognized Tax Benefits 6.43M USD +124%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 47.5K USD +272%
Deferred Tax Assets, Net of Valuation Allowance 50K USD +234%
Share-based Payment Arrangement, Expense 6.82M USD +1082%
Interest Expense 1.32M USD +173%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%